Matthew Barcus
Stock Analyst at Chardan Capital
(0.29)
# 2558
Out of 5,331 analysts
36
Total ratings
26.09%
Success rate
2.95%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
ZURA Zura Bio | Maintains: Buy | 12 10 | 1.47 | 580.27% | 3 | Mar 26, 2025 | |
QURE uniQure | Maintains: Buy | 45 27 | 14.8 | 82.43% | 4 | Jun 22, 2023 | |
XLO Xilio Therapeutics | Reiterates: Buy | 7 | 0.75 | 833.33% | 3 | May 30, 2023 | |
IMVT Immunovant | Maintains: Strong Buy | 21 32 | 15.82 | 102.28% | 4 | May 23, 2023 | |
PPBT Purple Biotech | Reiterates: Buy | 220 | 2.34 | 9301.71% | 3 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 144 126 | n/a | n/a | 3 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 9 | 2.78 | 223.74% | 3 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 9 8 | 8.87 | -9.81% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Dec 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 80 60 | n/a | n/a | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Jul 21, 2022 |